Company Filing History:
Years Active: 2022-2025
Title: Mark Schmidt: Innovator in Depression Treatment
Introduction
Mark Schmidt is a notable inventor based in Antwerp, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of depression. With a total of 8 patents to his name, Schmidt's work is focused on developing innovative methods and compositions for addressing major depressive disorders.
Latest Patents
One of Schmidt's latest patents is titled "Compositions and methods for the treatment of depression." This patent provides methods for treating major depressive disorder in human patients experiencing moderate or severe anhedonia. The methods involve administering an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof, to patients who have had inadequate responses to other antidepressant therapies. In some cases, these therapies include selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Another significant patent is focused on compositions comprising aticaprant, which includes oral formulations in the form of tablets.
Career Highlights
Mark Schmidt is currently employed at Janssen Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work is pivotal in creating effective treatments for individuals suffering from depression, showcasing his commitment to improving mental health outcomes.
Collaborations
Schmidt collaborates with talented professionals in his field, including colleagues such as Vanina Popova and Adam Savitz. These collaborations enhance the innovative potential of his projects and contribute to the overall success of their research initiatives.
Conclusion
Mark Schmidt's contributions to the treatment of depression through his innovative patents and collaborations highlight his role as a leading inventor in the pharmaceutical industry. His work continues to pave the way for new therapeutic options for patients in need.